Physician

Fernando Melocoton Abanilla, MD

According to 2025 Medicare claims, Fernando Abanilla, MD (NPI: 1558469338) practices nephrology in the Sebring, FL market, with the plurality of this provider's patient population coming from Highlands, FL. This provider's primary affiliated billing organization is F M ABANILLA MD PA (NPI: 1245414911; TIN: 65-0629124) and primary practice location at 33872-1986.

Abanilla's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 366 traditional Medicare patients, billed 2,032 HCPCS/CPT codes, and received $196,600 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 3,681 prescription claims across 417 beneficiaries totaling $1,155,902 in drug costs, led by Jardiance (Empagliflozin). DME data shows 80 claims. Open Payments data shows 4 records totaling $215. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $322,849 to $196,600. In contrast, Part D prescription costs have moved sharply higher in recent years, from $406,766 to $1,155,902. For DME billing, this smaller-volume category declined steadily, from $7,144 to $3,187.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$161K$323K2015 Medicare payment: $322,849 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $304,959 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $277,257 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $268,510 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $308,882 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $322,109 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $320,480 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $273,421 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $205,213 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $196,600 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20157243,370$322,849
20167773,364$304,959
20177173,200$277,257
20186722,963$268,510
20197083,270$308,882
20206133,452$322,109
20215443,344$320,480
20225142,872$273,421
20234482,238$205,213
20243662,032$196,600

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$578K$1.2M2015 Drug cost: $406,766 (USD; Tot_Drug_Cst)2016 Drug cost: $493,885 (USD; Tot_Drug_Cst)2017 Drug cost: $393,547 (USD; Tot_Drug_Cst)2018 Drug cost: $259,979 (USD; Tot_Drug_Cst)2019 Drug cost: $255,856 (USD; Tot_Drug_Cst)2020 Drug cost: $274,924 (USD; Tot_Drug_Cst)2021 Drug cost: $315,022 (USD; Tot_Drug_Cst)2022 Drug cost: $490,884 (USD; Tot_Drug_Cst)2023 Drug cost: $882,312 (USD; Tot_Drug_Cst)2024 Drug cost: $1,155,902 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20153583,926$406,766
20163773,585$493,885
20173793,407$393,547
20183853,103$259,979
20193562,822$255,856
20203312,697$274,924
20213412,625$315,022
20223342,496$490,884
20233513,046$882,312
20244173,681$1,155,902

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$3.4K$6.8K2015 Medicare payment: $6,769 (USD; DME_Suplr_Mdcr_Pymt_Amt)2016 Medicare payment: $3,560 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $4,240 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $5,740 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $1,698 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $367 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $3,156 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $3,124 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $2,709 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $1,021 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
201517111$6,769
201616116$3,560
20171379$4,240
201815166$5,740
2019N/R36$1,698
2020N/R11$367
2021N/R45$3,156
2022N/R42$3,124
2023N/R102$2,709
2024N/R80$1,021

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99223Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes110131$125
99215Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more140167$116
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more217369$87
99233Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes126506$86
99232Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes81207$57

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
JardianceEmpagliflozin35716,673$329,322
FarxigaDapagliflozin Propanediol30514,194$262,760
RybelsusSemaglutide1014,887$155,370
OzempicSemaglutide692,394$69,115
EntrestoSacubitril/Valsartan603,004$61,298

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodNN/R27$313
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodNN/R14$245
J7518Mycophenolic acid, oral, 180 mgNN/R13$240
J7507Tacrolimus, immediate release, oral, 1 mgNN/R13$213
J7512Prednisone, immediate release or delayed release, oral, 1 mgNN/R13$9

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.4$215AstraZeneca Pharmaceuticals LP
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Fernando Melocoton Abanilla, MD?

Tedicare shows public-source Medicare data for Fernando Melocoton Abanilla, MD (NPI 1558469338), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Fernando Melocoton Abanilla, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Fernando Melocoton Abanilla, MD?

Fernando Melocoton Abanilla, MD is linked to F M ABANILLA MD PA (billing NPI 1245414911) in the available physician profile data.

Does Fernando Melocoton Abanilla, MD have Open Payments data?

Fernando Melocoton Abanilla, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.